Aliases & Classifications for Immune System Disease

MalaCards integrated aliases for Immune System Disease:

Name: Immune System Disease 12 15 17
Abnormality of the Immune System 29
Immune System and Disorders 42
Immune System Diseases 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2914
ICD9CM 34 279 279.9
ICD10 32 D89.9
UMLS 71 C0021053 C0041806

Summaries for Immune System Disease

MedlinePlus : 42 Your immune system is a complex network of cells, tissues, and organs that work together to defend against germs. It helps your body to recognize these "foreign" invaders. Then its job is to keep them out, or if it can't, to find and destroy them. If your immune system cannot do its job, the results can be serious. Disorders of the immune system include Allergy and asthma - immune responses to substances that are usually not harmful Immune deficiency diseases - disorders in which the immune system is missing one or more of its parts Autoimmune diseases - diseases causing your immune system to attack your own body's cells and tissues by mistake

MalaCards based summary : Immune System Disease, also known as abnormality of the immune system, is related to immune deficiency disease and temporal arteritis, and has symptoms including pathological conditions, signs and symptoms An important gene associated with Immune System Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and MicroRNAs in cancer. The drugs Midazolam and Morphine have been mentioned in the context of this disorder. Affiliated tissues include immune system, t cells and b cells.

Disease Ontology : 12 A disease of anatomical entity that is located in the immune system.

Related Diseases for Immune System Disease

Diseases related to Immune System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 439)
# Related Disease Score Top Affiliating Genes
1 immune deficiency disease 34.1 IRF4 ICOSLG H2AC18 CFHR2 CD40LG CD4
2 temporal arteritis 32.9 SERPINA3 CD8A CD40LG CD4 CCR6
3 lymphatic system disease 32.9 U2AF1 SERPINA3 MIR17 MIR150 MIR125A IRF4
4 herpes zoster 32.8 ICOSLG CD8A CD40LG CD4
5 allergic hypersensitivity disease 32.8 ICOSLG H2AC18 CD4 CCR6
6 bacterial infectious disease 31.0 SERPINA3 MIR155 ICOSLG H2AC18 CD8A CD40LG
7 immunoglobulin alpha deficiency 31.0 ICOSLG CD8A CD40LG CD4 CCR6
8 complement component 3 deficiency, autosomal recessive 11.5
9 autoimmune disease 11.3
10 trichohepatoenteric syndrome 1 11.0
11 autoinflammation, panniculitis, and dermatosis syndrome 11.0
12 vasculitis syndromes of the central and peripheral nervous systems 11.0
13 cervix disease 11.0 SERPINA3 MIR21 MIR17 MIR146A MIR142 MIR125A
14 hypersensitivity reaction type iv disease 11.0 SERPINA3 MIR155 ICOSLG H2AC18 CFHR2 CD8A
15 rheumatic disease 11.0 MIR155 MIR146A MIR142 ICOSLG H2AC18 CD40LG
16 muscle tissue disease 11.0 U2AF1 SERPINA3 MIR142 ICOSLG H2AC18 CCR6
17 intestinal benign neoplasm 11.0 SERPINA3 MIR21 MIR17 MIR142 H2AC18 CCR6
18 dermatomyositis 11.0 MIR223 MIR21 MIR155
19 mycobacterium tuberculosis 1 11.0 SERPINA3 MIR223 MIR21 MIR155 ICOSLG H2AC18
20 extrinsic cardiomyopathy 10.9 MIR223 MIR21 ICOSLG H2AC18 CD8A CD40LG
21 gastrointestinal system benign neoplasm 10.9 SERPINA3 MIR21 MIR17 MIR142 H2AC18 CCR6
22 overnutrition 10.9 SERPINA3 MIR223 MIR21 MIR17 MIR155 MIR142
23 autonomic nervous system neoplasm 10.9 U2AF1 SERPINA3 MIR17 MIR142 MIR125A ICOSLG
24 biliary tract disease 10.9 SERPINA3 MIR17 MIR150 MIR142 MIR125A ICOSLG
25 peripheral nervous system neoplasm 10.9 U2AF1 SERPINA3 MIR17 MIR142 MIR125A ICOSLG
26 esophageal disease 10.9 MIR223 MIR21 MIR17 MIR146A MIR142 MIR126
27 nasopharyngeal disease 10.9 MIR21 MIR17 MIR142 MIR125A ICOSLG H2AC18
28 ovary epithelial cancer 10.9 U2AF1 SERPINA3 MIR21 MIR17 MIR125A ICOSLG
29 cardiovascular system disease 10.9 SERPINA3 MIR223 MIR21 MIR17 MIR155 MIR146A
30 b-cell lymphoma 10.9 MIR21 MIR17 MIR155 MIR142 IRF4
31 thyroid gland disease 10.9 U2AF1 MIR21 MIR17 MIR146A MIR142 MIR125A
32 chediak-higashi syndrome 10.9 SERPINA3 ICOSLG H2AC18 CD8A CD4 CCR6
33 coccidiosis 10.9 SERPINA3 ICOSLG H2AC18 CD8A CD40LG CD4
34 cervix carcinoma 10.9 U2AF1 SERPINA3 MIR155 MIR150 MIR142 H2AC18
35 uveal disease 10.9 U2AF1 SERPINA3 MIR142 ICOSLG H2AC18 CFHR2
36 autoimmune disease of skin and connective tissue 10.9 SERPINA3 ICOSLG CD40LG CD4 CCR6
37 pharynx cancer 10.9 SERPINA3 MIR21 MIR17 MIR142 MIR125A H2AC18
38 mast cell neoplasm 10.9 U2AF1 SERPINA3 ICOSLG H2AC18 CD8A CD4
39 neuromuscular junction disease 10.9 SERPINA3 ICOSLG H2AC18 CD8A CD40LG CD4
40 listeriosis 10.9 ICOSLG H2AC18 CD8A CD4 CCR6
41 salivary gland disease 10.9 SERPINA3 ICOSLG H2AC18 CD8A CD40LG CD4
42 x-linked recessive disease 10.9 U2AF1 SERPINA3 MIR223 MIR142 ICOSLG H2AC18
43 x-linked monogenic disease 10.9 U2AF1 SERPINA3 MIR223 MIR142 ICOSLG H2AC18
44 spinal cord disease 10.9 MIR142 ICOSLG H2AC18 CD8A CD40LG CD4
45 bacterial pneumonia 10.9 MIR155 ICOSLG H2AC18 CD8A CD40LG CD4
46 uterine anomalies 10.9 U2AF1 SERPINA3 MIR21 MIR17 MIR146A MIR142
47 inherited metabolic disorder 10.9 SERPINA3 MIR21 MIR17 MIR142 MIR126 H2AC18
48 malignant ovarian surface epithelial-stromal neoplasm 10.9 SERPINA3 MIR21 MIR17 MIR125A ICOSLG H2AC18
49 collagen disease 10.9 SERPINA3 MIR223 MIR21 MIR142 ICOSLG H2AC18
50 intrinsic cardiomyopathy 10.9 MIR21 MIR146A MIR142 MIR126 ICOSLG H2AC18

Graphical network of the top 20 diseases related to Immune System Disease:



Diseases related to Immune System Disease

Symptoms & Phenotypes for Immune System Disease

UMLS symptoms related to Immune System Disease:


pathological conditions, signs and symptoms

Drugs & Therapeutics for Immune System Disease

Drugs for Immune System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 284)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
7
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
8
Busulfan Approved, Investigational Phase 4 55-98-1 2478
9
Hydroxychloroquine Approved Phase 4 118-42-3 3652
10
Adenosine Approved, Investigational Phase 4 58-61-7 60961
11
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
12
Treosulfan Investigational Phase 4 299-75-2 9296
13 Neurotransmitter Agents Phase 4
14 Immunoglobulin A Phase 4
15 Interferon-alpha Phase 4
16 GABA Agents Phase 4
17 Narcotics Phase 4
18 Anti-Anxiety Agents Phase 4
19 Tranquilizing Agents Phase 4
20 Adjuvants, Anesthesia Phase 4
21 Anesthetics, General Phase 4
22 Analgesics, Opioid Phase 4
23 GABA Modulators Phase 4
24 Psychotropic Drugs Phase 4
25 Hypnotics and Sedatives Phase 4
26 Anesthetics, Intravenous Phase 4
27 Central Nervous System Depressants Phase 4
28 Antihypertensive Agents Phase 4
29 Angiotensin II Type 1 Receptor Blockers Phase 4
30 Giapreza Phase 4
31 Angiotensin Receptor Antagonists Phase 4
32 Angiotensinogen Phase 4
33 Antitubercular Agents Phase 4
34 Fibrinolytic Agents Phase 4
35 Analgesics, Non-Narcotic Phase 4
36 Platelet Aggregation Inhibitors Phase 4
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4
38 Antipyretics Phase 4
39 Cyclooxygenase Inhibitors Phase 4
40 Analgesics Phase 4
41 Mesalamine Phase 4 89-57-6
42 Immunologic Factors Phase 4
43 Alkylating Agents Phase 4
44 Immunosuppressive Agents Phase 4
45 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
46 Antiparasitic Agents Phase 4
47 Antiprotozoal Agents Phase 4
48 Antimalarials Phase 4
49 Anticoagulants Phase 4
50
Histamine Approved, Investigational Phase 3 51-45-6 774

Interventional clinical trials:

(show top 50) (show all 214)
# Name Status NCT ID Phase Drugs
1 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
2 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
3 Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status. Unknown status NCT02135055 Phase 4 Midazolam;Morphine
4 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
5 The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Completed NCT01867281 Phase 4 aspirin
6 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
7 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo
8 Use of Traditional Chinese Medicine (Ren Shen Yang Rong Tang) Against Microinflammation in Hemodialysis Patients: A Quasi-randomized Controlled Trial Completed NCT02053740 Phase 4 Add R-S-Y-R-T (500 mg 3 times per day) for 6 months;Routine western medicine
9 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Recruiting NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
10 Evaluation of Immune Response to Vaccines in Primary Immune Disorders Recruiting NCT00023504 Phase 4
11 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
12 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
13 Methodology Study to Investigate the Utility of Retroviral Insertion Site Analysis in Samples From Subjects Treated With Strimvelis™ Gene Therapy Not yet recruiting NCT03311074 Phase 4
14 A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis Unknown status NCT02468791 Phase 3 Rituximab
15 A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Completed NCT03054428 Phase 3 Dupilumab;Placebo
16 A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis Completed NCT01918033 Phase 3 Desloratadine 5 mg;Placebo
17 A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus. Completed NCT01916980 Phase 3 Desloratadine 5 mg
18 A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria. Completed NCT01916967 Phase 3 Desloratadine;Placebo
19 A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00504075 Phase 3
20 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
21 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
22 A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks;Standard of Care
23 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease Completed NCT00035308 Phase 3 Abetimus sodium (LJP 394)
24 Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients Completed NCT01307332 Phase 3 MabCampath-1h
25 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
26 An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma Completed NCT00773747 Phase 3 vorinostat;bortezomib;placebo to vorinostat
27 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
28 A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma Recruiting NCT03629249 Phase 3 Placebo;QAW039 Dose 1;QAW039 Dose 2
29 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02549170 Phase 3
30 Effect of Early Oral Colostrum Administration Versus Placebo on the Immune System in Premature Newborns Under 32 Weeks of Gestation: A Randomized Clinical Trial. Active, not recruiting NCT03578341 Phase 3
31 A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus. Active, not recruiting NCT02794285 Phase 3 Placebo
32 A Randomized, Open-label Trial to Compare the Efficacy and Safety of Early Initiation of cART With or Without Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in Treatment-Naïve Acute HIV-1 Infected Adults Active, not recruiting NCT02231281 Phase 3 cART(TDF/AZT+3TC+LPV/r)
33 A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS Active, not recruiting NCT03627767 Phase 3 PF-04965842 100 mg;PF-04965842 200 mg;Placebo
34 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment Active, not recruiting NCT03170271 Phase 3 Benralizumab (Medi-563);Placebo
35 A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS Active, not recruiting NCT03720470 Phase 3 PF-04965842 100 mg;PF-04965842 200 mg;Dupilumab;Oral Placebo;Injectable Placebo
36 A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X) Terminated NCT01488708 Phase 3 LY2127399;Placebo
37 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
38 A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Terminated NCT01650805 Phase 3 ponatinib;imatinib (Gleevec/ Glivec)
39 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL Terminated NCT02366663 Phase 3 Carmustine;Etoposide;Cytarabine;Melphalan
40 Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease Terminated NCT02411084 Phase 3
41 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis Withdrawn NCT02677636 Phase 3 MSRD-100;Vehicle
42 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis Withdrawn NCT02677610 Phase 3 MSRD-100;Vehicle
43 Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial Unknown status NCT02594878 Phase 2 Pamidronatdinatrium
44 The Effect of Subantimicrobial Dose Doxycycline in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
45 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
46 Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy. Unknown status NCT01687192 Phase 2
47 Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
48 Extract Allergen From Betula Verrucosa. Test Sensitivity and Specificity of Diagnostic in Prick Test Preparation Completed NCT02527187 Phase 2
49 High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT02294552 Phase 2 Cyclophosphamide;Busulfan;Fludarabine monophosphate;Tacrolimus;Mycophenolate mofetil
50 DMT210 Topical Gel in the Treatment of Mild to Moderate Atopic Dermatitis Completed NCT02949960 Phase 2 DMT210 Topical Gel;Vehicle Control

Search NIH Clinical Center for Immune System Disease

Genetic Tests for Immune System Disease

Genetic tests related to Immune System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Immune System 29

Anatomical Context for Immune System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Immune System Disease:

19
Immune System

MalaCards organs/tissues related to Immune System Disease:

40
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Skin, Lung

Publications for Immune System Disease

Articles related to Immune System Disease:

(show top 50) (show all 105)
# Title Authors PMID Year
1
How does the immune system learn to distinguish between good and evil? The first definitive studies of T cell central tolerance and positive selection. 42
31418051 2019
2
Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy. 42
31261963 2019
3
NF-κB, IκB, and IKK: Integral Components of Immune System Signaling. 42
31628658 2019
4
Case report on a 32-year-old female with elevated serum creatinine levels and primary Sjögren's syndrome-chronic interstitial nephritis. 61
31772632 2019
5
Co-evaluation of interaction parameters of genomic and plasmid DNA for a new chromatographic medium. 61
31520707 2019
6
Prevalence of CCR5delta32 in Northeastern Iran. 61
31730458 2019
7
Effect of different seasons (spring vs summer) on the microbiota diversity in the feces of dairy cows. 61
31707493 2019
8
Analysis of Panax ginseng miRNAs and Their Target Prediction Based on High-Throughput Sequencing. 61
31434113 2019
9
Trehalose suppresses cadmium-activated Nrf2 signaling pathway to protect against spleen injury. 61
31195231 2019
10
A link between environmental pollution and civilization disorders: a mini review. 61
31141493 2019
11
The gastrointestinal fate of limonin and its effect on gut microbiota in mice. 61
31418448 2019
12
High-Throughput Sequencing Reveals the Gut Microbiome of the Bactrian Camel in Different Ages. 61
31030270 2019
13
Statistical analysis of disease-causing and neutral mutations in human membrane proteins. 61
30714211 2019
14
Medicinal plants of the Caatinga, northeastern Brazil: Ethnopharmacopeia (1980-1990) of the late professor Francisco José de Abreu Matos. 61
30885881 2019
15
Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. 61
30515752 2019
16
Gut microbiota characterization and lipid metabolism disorder found in PCB77-treated female mice. 61
30935970 2019
17
Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. 61
30710597 2019
18
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. 61
30885723 2019
19
Mathematical Models for Possible Roles of Oxytocin and Oxytocin Receptors in Autism. 61
31827587 2019
20
Distinct Gut Microbiota Composition and Functional Category in Children With Cerebral Palsy and Epilepsy. 61
31646147 2019
21
Muscular Tuberculosis: A New Case and a Review of the Literature. 61
31632334 2019
22
Epigenetic Modification Related to Acetylation of Histone and Methylation of DNA as a Key Player in Immunological Disorders. 61
31002589 2019
23
Effects of Captivity and Season on the Gut Microbiota of the Brown Frog (Rana dybowskii). 61
31507549 2019
24
The Variation of Nasal Microbiota Caused by Low Levels of Gaseous Ammonia Exposure in Growing Pigs. 61
31156592 2019
25
Computational comparison of two new fusion proteins for multiple sclerosis. 61
30271441 2018
26
Stiff person syndrome with elevated titers of antibodies against cardiolipin and β2 glycoprotein 1: a case report and literature review. 61
30179217 2018
27
Cinnamaldehyde protects VSMCs against ox-LDL-induced proliferation and migration through S arrest and inhibition of p38, JNK/MAPKs and NF-κB. 61
29777873 2018
28
Porcine cluster of differentiation (CD) markers 2018 update. 61
29518710 2018
29
Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. 61
29682215 2018
30
[Diffusion of Microorganism and Main Pathogenic Bacteria During Municipal Treated Wastewater Discharged into Sea]. 61
29965485 2018
31
Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. 61
29360814 2018
32
Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice. 61
30337870 2018
33
The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses. 61
29141575 2018
34
The vitamin D receptor and the etiology of RANTES/CCL-expressive fatty-degenerative osteolysis of the jawbone: an interface between osteoimmunology and bone metabolism. 61
29731660 2018
35
Comparative transcriptome analysis of Eriocheir japonica sinensis response to environmental salinity. 61
30192896 2018
36
Research Techniques Made Simple: Murine Models of Human Psoriasis. 61
29273150 2018
37
Integrated strategy of differentially expressed genes associated with ulcerative colitis. 61
28944823 2017
38
[Clinical applications of stem cells from human exfoliated deciduous teeth in stem cell therapy]. 61
29188652 2017
39
Medical comorbidities in children and adolescents with autism spectrum disorders and attention deficit hyperactivity disorders: a systematic review. 61
28674760 2017
40
Identification of Sequence Variants within Experimentally Validated Protein Interaction Sites Provides New Insights into Molecular Mechanisms of Disease Development. 61
28452122 2017
41
Fractalkine (C-X3-C motif chemokine ligand 1) as a potential biomarker for depression and anxiety in colorectal cancer patients. 61
28804633 2017
42
Kinetic analysis of IgM monoclonal antibodies for determination of dengue sample concentration using SPR technique. 61
27533620 2017
43
Investigation of Sex Differences In sIgA Response to the Trier Social Stress Test. 61
27075235 2017
44
The Importance of Immune System Diseases in the Etiology of Attention-Deficit/Hyperactivity Disorder. 61
28137376 2017
45
Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases. 61
26809250 2017
46
Toxicogenomic analysis of the pulmonary toxic effects of hexanal in F344 rat. 61
26880647 2017
47
Immunostimulatory Effect of Enzyme-Modified Hizikia fusiformein a Mouse Model In Vitro and Ex Vivo. 61
28138935 2017
48
Analysis of Clinical Characteristics of Immune-Related Dry Eye. 61
28638660 2017
49
Pharmacokinetics, Tissue Distribution, and Metabolism Study of Icariin in Rat. 61
29259982 2017
50
ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome. 61
28124611 2017

Variations for Immune System Disease

Expression for Immune System Disease

Search GEO for disease gene expression data for Immune System Disease.

Pathways for Immune System Disease

GO Terms for Immune System Disease

Cellular components related to Immune System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 SERPINA3 MIR223 MIR21 MIR17 MIR155 MIR150
2 external side of plasma membrane GO:0009897 9.35 ICOSLG CD8A CD40LG CD4 CCR6

Biological processes related to Immune System Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 MIR223 MIR21 MIR155 MIR146A MIR125A
2 positive regulation of inflammatory response GO:0050729 9.77 MIR21 MIR155 MIR126
3 negative regulation of gene expression GO:0010629 9.77 MIR21 MIR17 MIR155 MIR146A MIR125A
4 cellular response to hypoxia GO:0071456 9.76 MIR17 MIR155 MIR146A MIR126
5 negative regulation of inflammatory response GO:0050728 9.73 MIR223 MIR155 MIR146A MIR126
6 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.65 MIR150 MIR146A MIR126
7 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.6 IRF4 CD4
8 positive regulation of microglial cell activation GO:1903980 9.58 MIR155 MIR142
9 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.58 MIR155 MIR146A
10 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.58 MIR223 MIR21 MIR146A
11 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR17 MIR155
12 positive regulation of metalloendopeptidase activity GO:1904685 9.56 MIR21 MIR17
13 negative regulation of regulatory T cell differentiation GO:0045590 9.54 MIR21 MIR155
14 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.52 MIR21 MIR17
15 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.51 MIR155 MIR146A
16 positive regulation of sprouting angiogenesis GO:1903672 9.5 MIR155 MIR126 MIR125A
17 negative regulation of necrotic cell death GO:0060547 9.49 MIR223 MIR155
18 miRNA mediated inhibition of translation GO:0035278 9.46 MIR21 MIR17 MIR155 MIR146A
19 positive regulation of activated T cell proliferation GO:0042104 9.43 MIR21 MIR155 ICOSLG
20 T cell activation GO:0042110 9.26 IRF4 ICOSLG CD8A CD4
21 gene silencing by miRNA GO:0035195 9.23 MIR223 MIR21 MIR17 MIR155 MIR150 MIR146A

Molecular functions related to Immune System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR223 MIR21 MIR17 MIR155 MIR150 MIR146A

Sources for Immune System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....